ストックスクリーナーアプリを入手
29.57
3.33%
0.93
Beam Therapeutics Inc (BEAM) 最新ニュース
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Yahoo Finance
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
BEAM Technical Analysis | Trend, Signals & Chart Patterns | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? - Yahoo Finance
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
HC Wainwright Expects Lower Earnings for Beam Therapeutics - MarketBeat
BEAM News Today | Why did Beam Therapeutics stock go up today? - MarketBeat
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 8%Should You Sell? - MarketBeat
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 – Company Announcement - Financial Times
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - Barchart.com
Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com India
Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com South Africa
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):